Geron (GERN) Work In Process (2024)

Geron's (GERN) quarterly Work In Process came in at $30.1 million in Q4 2024, up 122.19% quarter-over-quarter from $13.5 million in Q3 2024.

Geron (GERN) Work In Process (2024) Analysis & Trends

Geron has disclosed Work In Process across 1 years of filings, most recently posting $30.1 million for Q4 2024.

  • Work In Process for Q4 2024 came in at $30.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $30.1 million (changed N/A YoY), and the FY2024 annual result was $30.1 million, changed N/A from the prior year.
  • Work In Process came in at $30.1 million for Q4 2024 at Geron, up from $13.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $30.1 million in Q4 2024 to a low of $13.5 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 Geron 729,618.77 729,618.77 -

Historic Data

Download Data
DateValue
Dec 31, 2024 30.09 Mn
Sep 30, 2024 13.54 Mn